Amivantamab (Rybrevant®) developed by Janssen Biologics is a bispecific antibody targeting c-MET/HGFR and EGFR. The drug was approved by the US FDA on May 21, 2021 for the treatment of non-small cell lung cancer with EGFR mutations [1].

Lung cancer is the most common type of tumor, and it is also a tumor with high mortality worldwide. About 80-85% of lung cancer patients are non-small cell lung cancer. 2~3% of patients with non-small cell lung cancer have EGFR exon 20 insertion mutations. This mutation form is the third most common EGFR mutation, which can lead to the rapid proliferation and migration of tumor cells [2].

Amivantamab was approved based on a multi-center, open-label, multi-cohort trial that included 81 NSCLC patients with EGFR exon 20 insertion mutations. The data showed that the overall remission rate ORR was 40%, the median duration of remission was 11.1 months, and the duration of remission was more than 6 months in 63% of patients (NCT02609776) [3].